A form of MACULAR DEGENERATION also known as dry macular degeneration marked by occurrence of a well-defined progressive lesion or atrophy in the central part of the RETINA called the MACULA LUTEA. It is distinguishable from WET MACULAR DEGENERATION in that the latter involves neovascular exudates.
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Colloid or hyaline bodies lying beneath the retinal pigment epithelium. They may occur either secondary to changes in the choroid that affect the pigment epithelium or as an autosomal dominant disorder of the retinal pigment epithelium.
Visualization of a vascular system after intravenous injection of a fluorescein solution. The images may be photographed or televised. It is used especially in studying the retinal and uveal vasculature.
Examination of the interior of the eye with an ophthalmoscope.
The single layer of pigment-containing epithelial cells in the RETINA, situated closely to the tips (outer segments) of the RETINAL PHOTORECEPTOR CELLS. These epithelial cells are macroglia that perform essential functions for the photoreceptor cells, such as in nutrient transport, phagocytosis of the shed photoreceptor membranes, and ensuring retinal attachment.
The concave interior of the eye, consisting of the retina, the choroid, the sclera, the optic disk, and blood vessels, seen by means of the ophthalmoscope. (Cline et al., Dictionary of Visual Science, 4th ed)
Optic disk bodies composed primarily of acid mucopolysaccharides that may produce pseudopapilledema (elevation of the optic disk without associated INTRACRANIAL HYPERTENSION) and visual field deficits. Drusen may also occur in the retina (see RETINAL DRUSEN). (Miller et al., Clinical Neuro-Ophthalmology, 4th ed, p355)
Atrophy of the optic disk which may be congenital or acquired. This condition indicates a deficiency in the number of nerve fibers which arise in the RETINA and converge to form the OPTIC DISK; OPTIC NERVE; OPTIC CHIASM; and optic tracts. GLAUCOMA; ISCHEMIA; inflammation, a chronic elevation of intracranial pressure, toxins, optic nerve compression, and inherited conditions (see OPTIC ATROPHIES, HEREDITARY) are relatively common causes of this condition.
A pathological process consisting of the formation of new blood vessels in the CHOROID.
The layer of pigment-containing epithelial cells in the RETINA; the CILIARY BODY; and the IRIS in the eye.
Inorganic salts of iodic acid (HIO3).
An oval area in the retina, 3 to 5 mm in diameter, usually located temporal to the posterior pole of the eye and slightly below the level of the optic disk. It is characterized by the presence of a yellow pigment diffusely permeating the inner layers, contains the fovea centralis in its center, and provides the best phototropic visual acuity. It is devoid of retinal blood vessels, except in its periphery, and receives nourishment from the choriocapillaris of the choroid. (From Cline et al., Dictionary of Visual Science, 4th ed)
Clarity or sharpness of OCULAR VISION or the ability of the eye to see fine details. Visual acuity depends on the functions of RETINA, neuronal transmission, and the interpretative ability of the brain. Normal visual acuity is expressed as 20/20 indicating that one can see at 20 feet what should normally be seen at that distance. Visual acuity can also be influenced by brightness, color, and contrast.
An imaging method using LASERS that is used for mapping subsurface structure. When a reflective site in the sample is at the same optical path length (coherence) as the reference mirror, the detector observes interference fringes.
Method of making images on a sensitized surface by exposure to light or other radiant energy.
Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.
A localized defect in the visual field bordered by an area of normal vision. This occurs with a variety of EYE DISEASES (e.g., RETINAL DISEASES and GLAUCOMA); OPTIC NERVE DISEASES, and other conditions.
A naturally occurring lipid pigment with histochemical characteristics similar to ceroid. It accumulates in various normal tissues and apparently increases in quantity with age.
The property of emitting radiation while being irradiated. The radiation emitted is usually of longer wavelength than that incident or absorbed, e.g., a substance can be irradiated with invisible radiation and emit visible light. X-ray fluorescence is used in diagnosis.
An important soluble regulator of the alternative pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It is a 139-kDa glycoprotein expressed by the liver and secreted into the blood. It binds to COMPLEMENT C3B and makes iC3b (inactivated complement 3b) susceptible to cleavage by COMPLEMENT FACTOR I. Complement factor H also inhibits the association of C3b with COMPLEMENT FACTOR B to form the C3bB proenzyme, and promotes the dissociation of Bb from the C3bBb complex (COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY).
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
The inner layer of CHOROID, also called the lamina basalis choroideae, located adjacent to the RETINAL PIGMENT EPITHELIUM; (RPE) of the EYE. It is a membrane composed of the basement membranes of the choriocapillaris ENDOTHELIUM and that of the RPE. The membrane stops at the OPTIC NERVE, as does the RPE.
An area approximately 1.5 millimeters in diameter within the macula lutea where the retina thins out greatly because of the oblique shifting of all layers except the pigment epithelium layer. It includes the sloping walls of the fovea (clivus) and contains a few rods in its periphery. In its center (foveola) are the cones most adapted to yield high visual acuity, each cone being connected to only one ganglion cell. (Cline et al., Dictionary of Visual Science, 4th ed)
A component of the CLASSICAL COMPLEMENT PATHWAY. C2 is cleaved by activated COMPLEMENT C1S into COMPLEMENT C2B and COMPLEMENT C2A. C2a, the COOH-terminal fragment containing a SERINE PROTEASE, combines with COMPLEMENT C4B to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
The thin, highly vascular membrane covering most of the posterior of the eye between the RETINA and SCLERA.
A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.
Method of measuring and mapping the scope of vision, from central to peripheral of each eye.
The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent.
Visual impairments limiting one or more of the basic functions of the eye: visual acuity, dark adaptation, color vision, or peripheral vision. These may result from EYE DISEASES; OPTIC NERVE DISEASES; VISUAL PATHWAY diseases; OCCIPITAL LOBE diseases; OCULAR MOTILITY DISORDERS; and other conditions (From Newell, Ophthalmology: Principles and Concepts, 7th ed, p132).
A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
The failure by the observer to measure or identify a phenomenon accurately, which results in an error. Sources for this may be due to the observer's missing an abnormality, or to faulty technique resulting in incorrect test measurement, or to misinterpretation of the data. Two varieties are inter-observer variation (the amount observers vary from one another when reporting on the same material) and intra-observer variation (the amount one observer varies between observations when reporting more than once on the same material).
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
A group of recessively inherited diseases that feature progressive muscular atrophy and hypotonia. They are classified as type I (Werdnig-Hoffman disease), type II (intermediate form), and type III (Kugelberg-Welander disease). Type I is fatal in infancy, type II has a late infantile onset and is associated with survival into the second or third decade. Type III has its onset in childhood, and is slowly progressive. (J Med Genet 1996 Apr:33(4):281-3)
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.

Autologous translocation of choroid and retinal pigment epithelium in geographic atrophy: long-term functional and anatomical outcome. (1/82)

 (+info)

Concordance of disease progression in bilateral geographic atrophy due to AMD. (2/82)

 (+info)

Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. (3/82)

 (+info)

{omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. (4/82)

 (+info)

CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. (5/82)

 (+info)

Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. (6/82)

 (+info)

Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD). (7/82)

 (+info)

Interferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. (8/82)

 (+info)

Geographic atrophy is a medical term used to describe a specific pattern of degeneration of the retinal pigment epithelium (RPE) and the underlying choroidal tissue in the eye. This condition is often associated with age-related macular degeneration (AMD), which is a leading cause of vision loss in older adults.

In geographic atrophy, there are well-defined areas of RPE and choroidal atrophy that appear as pale, irregularly shaped patches in the central part of the retina known as the macula. These patches can grow larger over time and may lead to progressive vision loss. The exact cause of geographic atrophy is not fully understood, but it is thought to be related to oxidative stress, inflammation, and other age-related changes in the eye.

Currently, there are no effective treatments for geographic atrophy, although research is ongoing to find new ways to slow or halt its progression. Regular eye exams and monitoring by an ophthalmologist are important for people with AMD or geographic atrophy to help detect any changes in their vision and manage their condition effectively.

Macular degeneration, also known as age-related macular degeneration (AMD), is a medical condition that affects the central part of the retina, called the macula. The macula is responsible for sharp, detailed vision, which is necessary for activities such as reading, driving, and recognizing faces.

In AMD, there is a breakdown or deterioration of the macula, leading to gradual loss of central vision. There are two main types of AMD: dry (atrophic) and wet (exudative). Dry AMD is more common and progresses more slowly, while wet AMD is less common but can cause rapid and severe vision loss if left untreated.

The exact causes of AMD are not fully understood, but risk factors include age, smoking, family history, high blood pressure, obesity, and exposure to sunlight. While there is no cure for AMD, treatments such as vitamin supplements, laser therapy, and medication injections can help slow its progression and reduce the risk of vision loss.

Atrophy is a medical term that refers to the decrease in size and wasting of an organ or tissue due to the disappearance of cells, shrinkage of cells, or decreased number of cells. This process can be caused by various factors such as disuse, aging, degeneration, injury, or disease.

For example, if a muscle is immobilized for an extended period, it may undergo atrophy due to lack of use. Similarly, certain medical conditions like diabetes, cancer, and heart failure can lead to the wasting away of various tissues and organs in the body.

Atrophy can also occur as a result of natural aging processes, leading to decreased muscle mass and strength in older adults. In general, atrophy is characterized by a decrease in the volume or weight of an organ or tissue, which can have significant impacts on its function and overall health.

Retinal drusen are yellow-white, deposits of extracellular material that accumulate beneath the retina, most commonly in the macula. They are a common age-related finding and can also be seen in various other conditions such as inherited retinal diseases. Drusen can vary in size and number, and their presence is often associated with an increased risk of developing age-related macular degeneration (AMD), a leading cause of vision loss in older adults. However, not all individuals with drusen will develop AMD, and the significance of drusen depends on factors such as size, number, and location. It's important to monitor drusen and have regular eye examinations to assess any changes or progression that may indicate a higher risk for developing AMD.

Fluorescein angiography is a medical diagnostic procedure used in ophthalmology to examine the blood flow in the retina and choroid, which are the inner layers of the eye. This test involves injecting a fluorescent dye, Fluorescein, into a patient's arm vein. As the dye reaches the blood vessels in the eye, a specialized camera takes rapid sequences of photographs to capture the dye's circulation through the retina and choroid.

The images produced by fluorescein angiography can help doctors identify any damage to the blood vessels, leakage, or abnormal growth of new blood vessels. This information is crucial in diagnosing and managing various eye conditions such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and inflammatory eye diseases.

It's important to note that while fluorescein angiography is a valuable diagnostic tool, it does carry some risks, including temporary side effects like nausea, vomiting, or allergic reactions to the dye. In rare cases, severe adverse reactions can occur, so patients should discuss these potential risks with their healthcare provider before undergoing the procedure.

Ophthalmoscopy is a medical examination technique used by healthcare professionals to observe the interior structures of the eye, including the retina, optic disc, and vitreous humor. This procedure typically involves using an ophthalmoscope, a handheld device that consists of a light and magnifying lenses. The healthcare provider looks through the ophthalmoscope and directly observes the internal structures of the eye by illuminating them.

There are several types of ophthalmoscopy, including direct ophthalmoscopy, indirect ophthalmoscopy, and slit-lamp biomicroscopy. Each type has its own advantages and disadvantages, and they may be used in different situations depending on the specific clinical situation and the information needed.

Ophthalmoscopy is an important diagnostic tool for detecting and monitoring a wide range of eye conditions, including diabetic retinopathy, glaucoma, age-related macular degeneration, and other retinal disorders. It can also provide valuable information about the overall health of the individual, as changes in the appearance of the retina or optic nerve may indicate the presence of systemic diseases such as hypertension or diabetes.

The retinal pigment epithelium (RPE) is a single layer of cells located between the photoreceptor cells of the retina and the choroid, which is a part of the eye containing blood vessels. The RPE plays a crucial role in maintaining the health and function of the photoreceptors by providing them with nutrients, removing waste products, and helping to regulate the light-sensitive visual pigments within the photoreceptors.

The RPE cells contain pigment granules that absorb excess light to prevent scattering within the eye and improve visual acuity. They also help to form the blood-retina barrier, which restricts the movement of certain molecules between the retina and the choroid, providing an important protective function for the retina.

Damage to the RPE can lead to a variety of eye conditions, including age-related macular degeneration (AMD), which is a leading cause of vision loss in older adults.

"Fundus Oculi" is a medical term that refers to the back part of the interior of the eye, including the optic disc, macula, fovea, retinal vasculature, and peripheral retina. It is the area where light is focused and then transmitted to the brain via the optic nerve, forming visual images. Examinations of the fundus oculi are crucial for detecting various eye conditions such as diabetic retinopathy, macular degeneration, glaucoma, and other retinal diseases. The examination is typically performed using an ophthalmoscope or a specialized camera called a retinal camera.

Optic disk drusen are small, calcified deposits that form within the optic nerve head, also known as the optic disc. They are made up of protein and calcium salts and can vary in size and number. These deposits can be seen on ophthalmic examination using an instrument called an ophthalmoscope.

Optic disk drusen are typically asymptomatic and are often discovered during routine eye examinations. However, in some cases, they may cause visual disturbances or even vision loss if they compress the optic nerve fibers. They can also increase the risk of developing other eye conditions such as glaucoma.

Optic disk drusen are more commonly found in individuals with a family history of the condition and tend to occur in younger people, typically before the age of 40. While there is no cure for optic disk drusen, regular eye examinations can help monitor any changes in the condition and manage any associated visual symptoms or complications.

Optic atrophy is a medical term that refers to the degeneration and shrinkage (atrophy) of the optic nerve, which transmits visual information from the eye to the brain. This condition can result in various vision abnormalities, including loss of visual acuity, color vision deficiencies, and peripheral vision loss.

Optic atrophy can occur due to a variety of causes, such as:

* Traumatic injuries to the eye or optic nerve
* Glaucoma
* Optic neuritis (inflammation of the optic nerve)
* Ischemic optic neuropathy (reduced blood flow to the optic nerve)
* Compression or swelling of the optic nerve
* Hereditary or congenital conditions affecting the optic nerve
* Toxins and certain medications that can damage the optic nerve.

The diagnosis of optic atrophy typically involves a comprehensive eye examination, including visual acuity testing, refraction assessment, slit-lamp examination, and dilated funduscopic examination to evaluate the health of the optic nerve. In some cases, additional diagnostic tests such as visual field testing, optical coherence tomography (OCT), or magnetic resonance imaging (MRI) may be necessary to confirm the diagnosis and determine the underlying cause.

There is no specific treatment for optic atrophy, but addressing the underlying cause can help prevent further damage to the optic nerve. In some cases, vision rehabilitation may be recommended to help patients adapt to their visual impairment.

Choroidal neovascularization (CNV) is a medical term that refers to the growth of new, abnormal blood vessels in the choroid layer of the eye, which is located between the retina and the sclera. This condition typically occurs as a complication of age-related macular degeneration (AMD), although it can also be caused by other eye diseases or injuries.

In CNV, the new blood vessels that grow into the choroid layer are fragile and can leak fluid or blood, which can cause distortion or damage to the retina, leading to vision loss. Symptoms of CNV may include blurred or distorted vision, a blind spot in the center of the visual field, or changes in color perception.

Treatment for CNV typically involves medications that are designed to stop the growth of new blood vessels, such as anti-VEGF drugs, which target a protein called vascular endothelial growth factor (VEGF) that is involved in the development of new blood vessels. Laser surgery or photodynamic therapy may also be used in some cases to destroy the abnormal blood vessels and prevent further vision loss.

The pigment epithelium of the eye, also known as the retinal pigment epithelium (RPE), is a layer of cells located between the photoreceptor cells of the retina and the choroid, which is the vascular layer of the eye. The RPE plays a crucial role in maintaining the health and function of the photoreceptors by providing them with nutrients, removing waste products, and helping to regulate the light that enters the eye.

The RPE cells contain pigment granules that absorb excess light, preventing it from scattering within the eye and improving visual acuity. They also help to create a barrier between the retina and the choroid, which is important for maintaining the proper functioning of the photoreceptors. Additionally, the RPE plays a role in the regeneration of visual pigments in the photoreceptor cells, allowing us to see in different light conditions.

Damage to the RPE can lead to various eye diseases and conditions, including age-related macular degeneration (AMD), which is a leading cause of vision loss in older adults.

Iodates are salts or esters of iodic acid (HIO3). They contain the iodate ion (IO3-) which consists of an iodine atom bonded to three oxygen atoms. Iodates are commonly used as a source of iodine in dietary supplements and in some disinfectants. In medicine, potassium iodate is used for the prevention of thyroid gland enlargement (goiter) caused by iodine deficiency. It works by providing the necessary iodine to the body.

The macula lutea, often simply referred to as the macula or fovea centralis, is a part of the eye that is responsible for central vision and color perception. It's located in the center of the retina, the light-sensitive tissue at the back of the eye. The macula contains a high concentration of pigments called xanthophylls, which give it a yellowish color and protect the photoreceptor cells in this area from damage by blue light.

The central part of the macula is called the fovea, which is a small depression that contains only cones, the photoreceptor cells responsible for color vision and high visual acuity. The fovea is surrounded by the parafovea and the perifovea, which contain both cones and rods, the photoreceptor cells responsible for low-light vision and peripheral vision.

Damage to the macula can result in a loss of central vision and color perception, a condition known as age-related macular degeneration (AMD), which is a leading cause of blindness in older adults. Other conditions that can affect the macula include macular edema, macular holes, and macular pucker.

Visual acuity is a measure of the sharpness or clarity of vision. It is usually tested by reading an eye chart from a specific distance, such as 20 feet (6 meters). The standard eye chart used for this purpose is called the Snellen chart, which contains rows of letters that decrease in size as you read down the chart.

Visual acuity is typically expressed as a fraction, with the numerator representing the testing distance and the denominator indicating the smallest line of type that can be read clearly. For example, if a person can read the line on the eye chart that corresponds to a visual acuity of 20/20, it means they have normal vision at 20 feet. If their visual acuity is 20/40, it means they must be as close as 20 feet to see what someone with normal vision can see at 40 feet.

It's important to note that visual acuity is just one aspect of overall vision and does not necessarily reflect other important factors such as peripheral vision, depth perception, color vision, or contrast sensitivity.

Optical coherence tomography (OCT) is a non-invasive imaging technique that uses low-coherence light to capture high-resolution cross-sectional images of biological tissues, particularly the retina and other ocular structures. OCT works by measuring the echo time delay of light scattered back from different depths within the tissue, creating a detailed map of the tissue's structure. This technique is widely used in ophthalmology to diagnose and monitor various eye conditions such as macular degeneration, diabetic retinopathy, and glaucoma.

I'm sorry for any confusion, but "photography" is not a term typically used in medical definitions. Photography refers to the art, application, or process of creating images by recording light or other electromagnetic radiation, either electronically by means of an image sensor, or chemically by means of a light-sensitive material such as photographic film.

If you're looking for a medical term related to imaging, there are several terms that might be relevant, such as:

1. Radiography: This is a technique using X-rays to visualize the internal structures of the body.
2. Ultrasonography: Also known as ultrasound, this is a diagnostic imaging technique using high-frequency sound waves to create images of the inside of the body.
3. Computed Tomography (CT): A type of imaging that uses X-rays to create detailed cross-sectional images of the body.
4. Magnetic Resonance Imaging (MRI): A type of imaging that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
5. Nuclear Medicine: This is a branch of medical imaging that uses small amounts of radioactive material to diagnose and treat diseases.

If you have any questions related to medical definitions or topics, feel free to ask!

Muscular atrophy is a condition characterized by a decrease in the size and mass of muscles due to lack of use, disease, or injury. This occurs when there is a disruption in the balance between muscle protein synthesis and degradation, leading to a net loss of muscle proteins. There are two main types of muscular atrophy:

1. Disuse atrophy: This type of atrophy occurs when muscles are not used or are immobilized for an extended period, such as after an injury, surgery, or prolonged bed rest. In this case, the nerves that control the muscles may still be functioning properly, but the muscles themselves waste away due to lack of use.
2. Neurogenic atrophy: This type of atrophy is caused by damage to the nerves that supply the muscles, leading to muscle weakness and wasting. Conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injuries, and peripheral neuropathies can cause neurogenic atrophy.

In both cases, the affected muscles may become weak, shrink in size, and lose their tone and mass. Treatment for muscular atrophy depends on the underlying cause and may include physical therapy, exercise, and medication to manage symptoms and improve muscle strength and function.

A scotoma is a blind spot or area of reduced vision within the visual field. It's often surrounded by an area of less distinct vision and can be caused by various conditions such as eye diseases, neurological disorders, or brain injuries. A scotoma may be temporary or permanent, depending on its underlying cause.

There are different types of scotomas, including:

1. Central scotoma - a blind spot in the center of the visual field, often associated with conditions like age-related macular degeneration and diabetic retinopathy.
2. Paracentral scotoma - a blind spot located slightly away from the center of the visual field, which can be caused by optic neuritis or other optic nerve disorders.
3. Peripheral scotoma - a blind spot in the peripheral vision, often associated with retinal diseases like retinitis pigmentosa.
4. Absolute scotoma - a complete loss of vision in a specific area of the visual field.
5. Relative scotoma - a partial loss of vision in which some details can still be perceived, but not as clearly or vividly as in normal vision.

It is essential to consult an eye care professional if you experience any changes in your vision or notice a scotoma, as early detection and treatment can help prevent further vision loss.

Lipofuscin is a type of pigment that accumulates in the lysosomes (membrane-bound organelles found inside cells) of various tissues, particularly in nerve cells and heart muscle cells. It consists of cross-linked proteins and lipids that are resistant to degradation by enzymes. The accumulation of lipofuscin is a normal part of aging but can also be associated with certain diseases such as neurodegenerative disorders.

It's often referred to as "age pigment" because it tends to increase in amount with age, and its presence in tissues has been linked to oxidative stress and cellular damage caused by free radicals. Lipofuscin is autofluorescent, meaning that it emits light when excited by certain wavelengths of light, which can be useful for its detection and quantification in research and diagnostic settings.

Fluorescence is not a medical term per se, but it is widely used in the medical field, particularly in diagnostic tests, medical devices, and research. Fluorescence is a physical phenomenon where a substance absorbs light at a specific wavelength and then emits light at a longer wavelength. This process, often referred to as fluorescing, results in the emission of visible light that can be detected and measured.

In medical terms, fluorescence is used in various applications such as:

1. In-vivo imaging: Fluorescent dyes or probes are introduced into the body to highlight specific structures, cells, or molecules during imaging procedures. This technique can help doctors detect and diagnose diseases such as cancer, inflammation, or infection.
2. Microscopy: Fluorescence microscopy is a powerful tool for visualizing biological samples at the cellular and molecular level. By labeling specific proteins, nucleic acids, or other molecules with fluorescent dyes, researchers can observe their distribution, interactions, and dynamics within cells and tissues.
3. Surgical guidance: Fluorescence-guided surgery is a technique where surgeons use fluorescent markers to identify critical structures such as blood vessels, nerves, or tumors during surgical procedures. This helps ensure precise and safe surgical interventions.
4. Diagnostic tests: Fluorescence-based assays are used in various diagnostic tests to detect and quantify specific biomarkers or analytes. These assays can be performed using techniques such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), or flow cytometry.

In summary, fluorescence is a physical process where a substance absorbs and emits light at different wavelengths. In the medical field, this phenomenon is harnessed for various applications such as in-vivo imaging, microscopy, surgical guidance, and diagnostic tests.

Complement Factor H is a protein involved in the regulation of the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Specifically, Complement Factor H helps to regulate the activation and deactivation of the complement component C3b, preventing excessive or unwanted activation of the complement system and protecting host tissues from damage.

Complement Factor H is a crucial protein in maintaining the balance between the protective effects of the complement system and the potential for harm to the body's own cells and tissues. Deficiencies or mutations in Complement Factor H have been associated with several diseases, including age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), and C3 glomerulopathy.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

The Bruch membrane is a thin, layered structure that separates the retina from the choroid in the eye. It is composed of five layers: the basement membrane of the retinal pigment epithelium (RPE), the inner collagenous layer, the elastic layer, the outer collagenous layer, and the basement membrane of the choriocapillaris. The Bruch membrane provides structural support to the RPE and serves as a barrier between the retina and the choroid, allowing for the selective transport of nutrients and waste products. It also plays a role in maintaining the health of the photoreceptors in the retina. Damage to the Bruch membrane is associated with age-related macular degeneration (AMD), a leading cause of vision loss in older adults.

The fovea centralis, also known as the macula lutea, is a small pit or depression located in the center of the retina, an light-sensitive tissue at the back of the eye. It is responsible for sharp, detailed vision (central vision) and color perception. The fovea contains only cones, the photoreceptor cells that are responsible for color vision and high visual acuity. It has a higher concentration of cones than any other area in the retina, allowing it to provide the greatest detail and color discrimination. The center of the fovea is called the foveola, which contains the highest density of cones and is avascular, meaning it lacks blood vessels to avoid interfering with the light passing through to the photoreceptor cells.

Complement C2 is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body. Specifically, C2 is a component of the classical complement pathway, which is activated by the binding of antibodies to antigens on the surface of foreign particles or cells.

When the classical pathway is activated, C2 is cleaved into two fragments: C2a and C2b. C2a then binds to C4b to form the C3 convertase (C4b2a), which cleaves C3 into C3a and C3b. C3b can then go on to form the membrane attack complex, which creates a pore in the membrane of the target cell, leading to its lysis.

In summary, Complement C2 is a protein that helps to activate the complement system and destroy foreign particles or cells through the formation of the C3 convertase and the membrane attack complex.

The choroid is a layer of the eye that contains blood vessels that supply oxygen and nutrients to the outer layers of the retina. It lies between the sclera (the white, protective coat of the eye) and the retina (the light-sensitive tissue at the back of the eye). The choroid is essential for maintaining the health and function of the retina, particularly the photoreceptor cells that detect light and transmit visual signals to the brain. Damage to the choroid can lead to vision loss or impairment.

Wet macular degeneration, also known as neovascular or exudative age-related macular degeneration (AMD), is a medical condition that affects the central part of the retina called the macula. It's characterized by the growth of new blood vessels (neovascularization) from the choroid layer behind the retina into the macula, which is not typical in healthy eyes. These abnormal blood vessels are fragile and prone to leakage, leading to the accumulation of fluid or blood in the macula, causing distortion or loss of central vision.

The wet form of AMD can progress rapidly and often leads to more severe visual loss compared to the dry form. It's essential to diagnose and treat wet AMD promptly to preserve as much vision as possible. Common treatments include anti-vascular endothelial growth factor (VEGF) injections, photodynamic therapy, or thermal laser treatment, depending on the specific case and individual patient factors.

A visual field test is a method used to measure an individual's entire scope of vision, which includes what can be seen straight ahead and in peripheral (or side) vision. During the test, the person being tested is asked to focus on a central point while gradually identifying the appearance of objects moving into their peripheral vision. The visual field test helps detect blind spots (scotomas) or gaps in the visual field, which can be caused by various conditions such as glaucoma, brain injury, optic nerve damage, or retinal disorders. It's an essential tool for diagnosing and monitoring eye-related diseases and conditions.

The retina is the innermost, light-sensitive layer of tissue in the eye of many vertebrates and some cephalopods. It receives light that has been focused by the cornea and lens, converts it into neural signals, and sends these to the brain via the optic nerve. The retina contains several types of photoreceptor cells including rods (which handle vision in low light) and cones (which are active in bright light and are capable of color vision).

In medical terms, any pathological changes or diseases affecting the retinal structure and function can lead to visual impairment or blindness. Examples include age-related macular degeneration, diabetic retinopathy, retinal detachment, and retinitis pigmentosa among others.

Vision disorders refer to a wide range of conditions that affect the visual system and result in various symptoms, such as blurry vision, double vision, distorted vision, impaired depth perception, and difficulty with visual tracking or focusing. These disorders can be categorized into several types, including:

1. Refractive errors: These occur when the shape of the eye prevents light from focusing directly on the retina, resulting in blurry vision. Examples include myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision).
2. Strabismus: Also known as crossed eyes or walleye, strabismus is a misalignment of the eyes where they point in different directions, which can lead to double vision or loss of depth perception.
3. Amblyopia: Often called lazy eye, amblyopia is a condition where one eye has reduced vision due to lack of proper visual development during childhood. It may be caused by strabismus, refractive errors, or other factors that interfere with normal visual development.
4. Accommodative disorders: These involve problems with the focusing ability of the eyes, such as convergence insufficiency (difficulty focusing on close objects) and accommodative dysfunction (inability to maintain clear vision at different distances).
5. Binocular vision disorders: These affect how the eyes work together as a team, leading to issues like poor depth perception, eye strain, and headaches. Examples include convergence insufficiency, divergence excess, and suppression.
6. Ocular motility disorders: These involve problems with eye movement, such as nystagmus (involuntary eye movements), strabismus, or restricted extraocular muscle function.
7. Visual processing disorders: These affect the brain's ability to interpret and make sense of visual information, even when the eyes themselves are healthy. Symptoms may include difficulty with reading, recognizing shapes and objects, and understanding spatial relationships.
8. Low vision: This term refers to significant visual impairment that cannot be fully corrected with glasses, contact lenses, medication, or surgery. It includes conditions like macular degeneration, diabetic retinopathy, glaucoma, and cataracts.
9. Blindness: Complete loss of sight in both eyes, which can be caused by various factors such as injury, disease, or genetic conditions.

Spinal muscular atrophy (SMA) is a genetic disorder that affects the motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by a mutation in the survival motor neuron 1 (SMN1) gene, which results in a deficiency of SMN protein necessary for the survival of motor neurons.

There are several types of SMA, classified based on the age of onset and severity of symptoms. The most common type is type 1, also known as Werdnig-Hoffmann disease, which presents in infancy and is characterized by severe muscle weakness, hypotonia, and feeding difficulties. Other types include type 2 (intermediate SMA), type 3 (Kugelberg-Welander disease), and type 4 (adult-onset SMA).

The symptoms of SMA may include muscle wasting, fasciculations, weakness, hypotonia, respiratory difficulties, and mobility impairment. The diagnosis of SMA typically involves genetic testing to confirm the presence of a mutation in the SMN1 gene. Treatment options for SMA may include medications, physical therapy, assistive devices, and respiratory support.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects multiple systems in the body. It is characterized by a combination of symptoms including Parkinsonism (such as stiffness, slowness of movement, and tremors), cerebellar ataxia (lack of muscle coordination), autonomic dysfunction (problems with the autonomic nervous system which controls involuntary actions like heart rate, blood pressure, sweating, and digestion), and pyramidal signs (abnormalities in the corticospinal tracts that control voluntary movements).

The disorder is caused by the degeneration of nerve cells in various parts of the brain and spinal cord, leading to a loss of function in these areas. The exact cause of MSA is unknown, but it is thought to involve a combination of genetic and environmental factors. There is currently no cure for MSA, and treatment is focused on managing symptoms and improving quality of life.

Observer variation, also known as inter-observer variability or measurement agreement, refers to the difference in observations or measurements made by different observers or raters when evaluating the same subject or phenomenon. It is a common issue in various fields such as medicine, research, and quality control, where subjective assessments are involved.

In medical terms, observer variation can occur in various contexts, including:

1. Diagnostic tests: Different radiologists may interpret the same X-ray or MRI scan differently, leading to variations in diagnosis.
2. Clinical trials: Different researchers may have different interpretations of clinical outcomes or adverse events, affecting the consistency and reliability of trial results.
3. Medical records: Different healthcare providers may document medical histories, physical examinations, or treatment plans differently, leading to inconsistencies in patient care.
4. Pathology: Different pathologists may have varying interpretations of tissue samples or laboratory tests, affecting diagnostic accuracy.

Observer variation can be minimized through various methods, such as standardized assessment tools, training and calibration of observers, and statistical analysis of inter-rater reliability.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Genotype, in genetics, refers to the complete heritable genetic makeup of an individual organism, including all of its genes. It is the set of instructions contained in an organism's DNA for the development and function of that organism. The genotype is the basis for an individual's inherited traits, and it can be contrasted with an individual's phenotype, which refers to the observable physical or biochemical characteristics of an organism that result from the expression of its genes in combination with environmental influences.

It is important to note that an individual's genotype is not necessarily identical to their genetic sequence. Some genes have multiple forms called alleles, and an individual may inherit different alleles for a given gene from each parent. The combination of alleles that an individual inherits for a particular gene is known as their genotype for that gene.

Understanding an individual's genotype can provide important information about their susceptibility to certain diseases, their response to drugs and other treatments, and their risk of passing on inherited genetic disorders to their offspring.

Spinal muscular atrophies (SMAs) of childhood are a group of inherited neuromuscular disorders characterized by degeneration and loss of lower motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. The severity and age of onset can vary significantly, with some forms presenting in infancy and others in later childhood or even adulthood.

The most common form of SMA is 5q autosomal recessive SMA, also known as survival motor neuron (SMN) disease, which results from mutations in the SMN1 gene. The severity of this form can range from severe (type I or Werdnig-Hoffmann disease), intermediate (type II or chronic infantile neurodegenerative disorder), to mild (type III or Kugelberg-Welander disease).

Type I SMA is the most severe form, with onset before 6 months of age and rapid progression leading to death within the first two years of life if left untreated. Type II SMA has an onset between 6 and 18 months of age, with affected children never achieving the ability to walk independently. Type III SMA has a later onset, typically after 18 months of age, and is characterized by a slower progression, allowing for the ability to walk unaided, although mobility may be lost over time.

Other forms of childhood-onset SMA include autosomal dominant distal SMA, X-linked SMA, and spinal bulbar muscular atrophy (SBMA or Kennedy's disease). These forms have distinct genetic causes and clinical presentations.

In general, SMAs are characterized by muscle weakness, hypotonia, fasciculations, tongue atrophy, and depressed or absent deep tendon reflexes. Respiratory and nutritional support is often required in more severe cases. Recent advances in gene therapy have led to the development of disease-modifying treatments for some forms of SMA.

Single Nucleotide Polymorphism (SNP) is a type of genetic variation that occurs when a single nucleotide (A, T, C, or G) in the DNA sequence is altered. This alteration must occur in at least 1% of the population to be considered a SNP. These variations can help explain why some people are more susceptible to certain diseases than others and can also influence how an individual responds to certain medications. SNPs can serve as biological markers, helping scientists locate genes that are associated with disease. They can also provide information about an individual's ancestry and ethnic background.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Reproducibility of results in a medical context refers to the ability to obtain consistent and comparable findings when a particular experiment or study is repeated, either by the same researcher or by different researchers, following the same experimental protocol. It is an essential principle in scientific research that helps to ensure the validity and reliability of research findings.

In medical research, reproducibility of results is crucial for establishing the effectiveness and safety of new treatments, interventions, or diagnostic tools. It involves conducting well-designed studies with adequate sample sizes, appropriate statistical analyses, and transparent reporting of methods and findings to allow other researchers to replicate the study and confirm or refute the results.

The lack of reproducibility in medical research has become a significant concern in recent years, as several high-profile studies have failed to produce consistent findings when replicated by other researchers. This has led to increased scrutiny of research practices and a call for greater transparency, rigor, and standardization in the conduct and reporting of medical research.

... (GA), also known as atrophic age-related macular degeneration (AMD) or advanced dry AMD, is an advanced form ... Since patients with geographic atrophy are at higher risk for developing advanced wet AMD (neovascular AMD), this could be ... Geographic atrophy is a chronic disease, which leads to visual function loss. This often results in difficulties performing ... Diagnosis of geographic atrophy is made by an ophthalmologist in the clinic. Fundus autofluorescence and optical coherence ...
Genetic founder effects are likely to be responsible for the higher prevalence of SBMA observed in certain geographic regions. ... Lingual atrophy occurs later in the course of the disease, but the tongue may develop an unusual shape due to coexisting ... Spinal muscular atrophies Arvin, Shelley (2013-04-01). "Analysis of inconsistencies in terminology of spinal and bulbar ... Kennedy, W. R.; Alter, M.; Sung, J. H. (1968). "Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex- ...
Retinal pseudocysts may be related to geographic atrophy. A study found that 22% of eyes with geographic atrophy contained ... "Retinal Pseudocysts in Age-Related Geographic Atrophy". American Journal of Ophthalmology. 150 (2): 211-217.e1. doi:10.1016/j. ...
Geographic retinal dysplasia appears as an irregular or horseshoe-shaped area of mixed hyper or hyporeflectivity in the central ... Chickens Progressive retinal atrophy Gelatt, Kirk N. (ed.) (1999). Veterinary Ophthalmology (3rd ed.). Lippincott, Williams & ... Labrador Retriever - focal, multifocal, geographic, or complete retinal dysplasia. It can also be seen in combination with a ... Horses - Retinal dysplasia is bilateral, not inherited, and appears as multifocal or geographic disease. It is usually ...
"An Investigational Therapy for Geographic Atrophy in Age-Related Macular Degeneration". Gumbiner, Barry; Esteves, Brooke; Dell ... a monoclonal antibody against Beta amyloid for the treatment of Geographic Atrophy in Age-Related Macular Degeneration RN909, a ...
Clinical trial number NCT02686658 for "Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular ... Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. ... a New Treatment for Geographic Atrophy" (Press release). Astellas Pharma Inc. 4 August 2023. Retrieved 25 August 2023 - via PR ...
"Morphometric analysis of the macula in eyes with geographic atrophy due to age-related macular degeneration". Retina. 46 (4): 4 ...
The three layers that undergo atrophy in geographic atrophy are all adjacent to each other. The photoreceptors are the most ... The deepest layer that undergoes atrophy in geographic atrophy is called the choriocappilaris. It is a capillary network that ... In advanced stages of AMD, atrophy of the RPE (geographic atrophy) and/or development of new blood vessels (neovascularization ... and in geographic atrophy, there are three specific layers that undergo atrophy: the choriocapillaris, retinal pigment ...
... it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and ... "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular ... These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy. World ...
Other ocular defects including optic atrophy, microphthalmia, vitreitis, leukokoria and cataracts can also be seen. Most of the ... However, obtaining an accurate sense of prevalence by geographic region is difficult due to underreporting. Lymphocytic ... Other findings include chorioretinal scars, and optic atrophy. Chorioretinitis, which is followed by chorioretinal scarring, is ...
Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration ...
"FDA Approves Syfovre (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of ... In February 2023, the indication was updated to include the treatment of people with geographic atrophy secondary to age- ... Liao DS, Metlapally R, Joshi P (September 2022). "Pegcetacoplan treatment for geographic atrophy due to age-related macular ... Abstract and geographic atrophy of the retina.: ¶1 Pegcetacoplan is a complement inhibitor.: ¶11 : ¶11 The most common side ...
... geographic atrophy). The anti-oxidants and zinc supplements only reduced the risk of progression to wet macular degeneration. ...
90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration". Retina. ...
Genentech is evaluating anti-Factor D for geographic atrophy associated with dry age-related macular degeneration in a Phase II ... and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy". ... of a humanized antibody against Factor D of the human immune complement system to be tested for treating geographic atrophy ...
One review reported overall prevalence ranges of 0.1-14.3% for geographic tongue, 1.3-9.0% for "atrophy tongue" (atrophic ... Some consider geographic tongue to be an early stage of fissured tongue, since the two conditions often occur in combination. ... Geographic tongue, also termed benign migratory glossitis, is a common condition which usually affects the dorsal surface of ... Syphilis is now relatively rare, but the tertiary stage can cause diffuse glossitis and atrophy of lingual papillae, termed " ...
Diabetic retinopathy Geographic atrophy Hypertensive retinopathy Macular degeneration Posterior vitreous detachment Wang M, ...
... is characterized by areas of atrophy and depapillation (loss of papillae), leaving an erythematous (darker ... Geographic tongue is inversely associated with smoking and tobacco use. Sometimes geographic tongue is said to run in families ... A recent study has proven the link between geographic tongue (GT) and psoriasis - the presence of geographic tongue can be a ... In such cases, terms such as stomatitis erythema migrans, ectopic geographic tongue, areata migrans, geographic stomatitis, or ...
... with geographic atrophy (GA). There currently are no therapies approved by the U.S. Food and Drug Administration ("FDA") for ... Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration". www.yahoo.com. ... stop or reverse disease progression in geographic atrophy secondary to age-related macular degeneration. 12-month primary ...
Skeletal muscles are affected and show neurogenic atrophy. The size and shape of spinal cord at different levels are normal but ... and birthplaces of the ancestors of affected individuals do not show geographic clustering.[citation needed] Vuopala K, ...
National Geographic News. Ed Lein, "Genome-wide atlas of gene expression in the adult mouse brain", Nature, 6 December 2006 " ... and disorders such as Lou Gehrig's diseases and spinal muscular atrophy. The project was funded by an array of donors including ...
Acrodermatitis chronica atrophicans (Herxheimer disease, primary diffuse atrophy) Actinic elastosis (solar elastosis) ... Geographic tongue (benign migratory glossitis, benign migratory stomatitis, glossitis areata exfoliativa, glossitis areata ... central papillary atrophy) Melanocytic oral lesion Melkersson-Rosenthal syndrome Morsicatio buccarum (chronic cheek biting, ... progressive hemifacial atrophy) Progressive systemic sclerosis Relapsing polychondritis (atrophic polychondritis, systemic ...
... geographic atrophy macular degeneration) are the best candidate for treatment. Candidates for visual prosthetic implants find ...
... administration of drugs to induce unconsciousness prior to surgery Geographic atrophy, an advanced form of age-related macular ...
National Geographic Channel. Fama, Russell (June 2, 2012). "An Interview with Thor of Comic Store Heroes". Super Sidekick. " ... who was diagnosed at age 2 with spinal muscular atrophy, but interacts with other comics fans on her blog and at conventions. ... Videos: "The Challenge". National Geographic Channel. Retrieved June 29, 2012. "Comic Shop Featured in Reality Show". ICv2. ... Videos: "Super Collectors". National Geographic Channel. Midtown Comics official website (Webarchive template wayback links, ...
On 29 August 2019, United States Space Command was reestablished as a geographic combatant command. In response to advances by ... resulting in the inactivation of United States Space Command and beginning a period of atrophy in military space. The only ... On 29 August 2019, United States Space Command was reestablished as a geographic combatant command. The first real attempt to ...
Geographic tongue (benign migratory glossitis) - a common disorder which occasionally causes a burning sensation but is usually ... Glossitis Oral lichen planus Hypoglossal nerve weakness can cause atrophy and fasciculation of the tongue. Melkersson-Rosenthal ... The most common tongue conditions are geographic tongue, followed by fissured tongue and hairy tongue. Hippocrates, Galen and ...
IUCN Initiatives - Mammals - Analysis of Data - Geographic Patterns 2012 Archived 12 May 2013 at the Wayback Machine. IUCN. ... ISBN 978-0-85345-532-5. Shambaugh, David L. (2008). China's Communist Party: Atrophy and Adaptation. Washington, DC; Berkeley, ... IUCN Initiatives - Amphibians - Analysis of Data - Geographic Patterns 2012 Archived 12 May 2013 at the Wayback Machine. IUCN. ... Other variations in Chinese architecture are shown in vernacular styles associated with different geographic regions and ...
"NASA Muscle Atrophy Research (MARES) Website". Archived from the original on 4 May 2010. Lohuis TD, Harlow HJ, Beck TD (2007 ... Washington, DC: National Geographic Society. pp. 307-311. ISBN 978-0-87044-621-4. Cruz-Jentoft, AJ; Sayer, AA (29 June 2019). " ... Inactivity, malnutrition, disease, and aging can increase the breakdown leading to muscle atrophy or sarcopenia. Sarcopenia is ... involving prolonged periods of immobilization and weightlessness is known to result in muscle weakening and atrophy resulting ...
Different subspecies are found in different regions of the geographic range. They are found from sea level up to an elevation ... Once the breeding season has concluded, these structures atrophy. The time of onset of sexual maturity may be earlier or later ... The rationale for the listing includes an overall stable population, lack of major threats, and a widespread geographic ... A Taxonomic and Geographic Reference (3rd ed.). Johns Hopkins University Press. p. 298. ISBN 978-0-8018-8221-0. OCLC 62265494. ...
Living With Geographic Atrophy. My Life With Geographic Atrophy From diagnosis to management, one woman shares her story about ... THE FUTURE OF GEOGRAPHIC ATROPHY. Watch as WebMDs Chief Medical Officer John Whyte, MD, and other experts discuss the latest ... People with geographic atrophy are often at risk for social isolation, as vision impairment may affect the activities theyre ... Geographic atrophy is an advanced form of age-related macular degeneration. Learn more about the different stages, symptoms, ...
... is intended for the treatment of people with geographic atrophy secondary to age-related macular degeneration. Geographic ... Cite this: FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness - Medscape - Feb 17, 2023. ... Pegcetacoplan is approved for patients with geographic atrophy with or without subfoveal involvement. Clinical trials of the ... FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness. ...
The first two drugs showing promise in slowing the progression of geographic atrophy are poised for FDA approval. Will this ... Until recently, clinicians havent had a viable option to treat geographic atrophy (GA). This absence of treatment has ... around the atrophy," said Dr. Rosenfeld. "All of these measure-ments help predict the growth rate of atrophy and can be ... Atrophy scares us.". "Patients need to be counseled that if they convert to wet AMD, theyll need two injections, one for wet, ...
MBA describes the presentation of geographic atrophy in patients and how they are first affected by the disease. ... And so when we do talk to patients, how do I describe geographic atrophy, atrophy for that patient? I say, look, its a form of ... Veeral Sheth, MD, MBA: When we talk about geographic atrophy, one of the interesting things is, for the longest time, we really ... Veeral Sheth, MD, MBA describes the presentation of geographic atrophy in patients and how they are first affected by the ...
Geographic AtrophyMVRF2021-11-07T17:53:33+00:00 [vc_row][vc_column][vc_column_text]Geographic atrophy (GA) is the term used to ... FACT OR FICTION: Theres Some Good News for Dry AMD Patients with Geographic Atrophy (GA). [/vc_column_text][/vc_column][/vc_ ... Theres definitely good news for dry age-related macular degeneration (AMD) patients with geographic atrophy or GA, as its ... CLINICAL TRIALS FOR PATIENTS WITH DRY AMD AND GEOGRAPHIC ATROPHY The complement cascade is likely to play a major role in ...
... a new FDA approved drug used to treat Geographic Atrophy. ... Geographic Atrophy affects more than 1 million people in the U. ... Advancement in Geographic Atrophy Treatment. For more than 100 years, Wolfe Eye Clinic has been Iowas leader in the treatment ... Geographic Atrophy (GA). This drug is similar to other retinal treatments and the medication is administered via a painless ... who13.com/video/new-treatment-for-macular-degeneration-geographic-atrophy-sufferers/8516842/ ...
Geographic AtrophyPresbyopiaAMDBiosimilarsCOVID-19CataractCataract TherapeuticsCorneaDMEDry EyeGlaucomaIOLOCTOcular Allergy ... Iveric Bio partnering with actor Eric Stonestreet to raise awareness of geographic atrophy. September 20, 2023. David Hutton ... Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 2021;139(7):743-750. ... C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration. Ophthalmology. 2021;128(4):576- ...
... has dosed the first patient in its Phase II SIGLEC trial investigating AVD-104 as a treatment for geographic atrophy (GA) ... Posted in News , Tagged AMD, Aviceda Therapeutics, Geographic atrophy, Nanomedicine / nanotechnology, Ophthalmology, Phase II ... Posted in News , Tagged AMD, Aviceda Therapeutics, Geographic atrophy, Nanomedicine / nanotechnology, Ophthalmology, Phase II ... Partners use AI tools to advance novel drugs for geographic atrophy 24 April 2023 ...
Ray Therapeutics secures $4M from CIRM to develop optogenetic therapy treatment for geographic atrophy. Nickie Louise Posted On ... Advanced AMD is characterized by two types: neovascular AMD and geographic atrophy (GA). GA affects approximately 1.5 million ... Ray Therapeutics secures $4M from CIRM to develop optogenetic therapy treatment for geographic atrophy. ... an optogenetic therapy designed for treating geographic atrophy (GA), the advanced form of age-related macular degeneration ( ...
"Geographic atrophy has a devastating impact on patients lives and can lead to irreversible vision loss," Khanani said in a ... Iveric Bio partnering with actor Eric Stonestreet to raise awareness of geographic atrophy. September 20th 2023 ... Iveric Bio partnering with actor Eric Stonestreet to raise awareness of geographic atrophy. September 20th 2023 ... Iveric Bio partnering with actor Eric Stonestreet to raise awareness of geographic atrophy. September 20th 2023 ...
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy (ArMaDa). ...
Treating geographic atrophy (GA) with complement C3 inhibitor pegcetacoplan 15 mg (APL-2; Apellis Pharmaceuticals) resulted in ... What APL-2 means for geographic atrophy. July 21, 2018. Michelle Dalton, ELS ... 2. Apellis pharmaceuticals announces 18-month results of phase 2 study (FILLY) of APL-2 in geographic atrophy. http://investors ... the atrophy progressed at the same rate as sham, Dr. Steinle said. ...
Light sensitivity within areas of geographic atrophy secondary to age-related macular degeneration ... Light sensitivity within areas of geographic atrophy secondary to age-related macular degeneration ...
A wide variety of neurologic disorders may present with focal muscular atrophy (FMA). ... Focal atrophy of an individual muscle or group of muscles, often encountered clinically, may create diagnostic and therapeutic ... The geographic variations of some of these disorders probably reflect environmental conditions rather than genetic ... encoded search term (Focal Muscular Atrophies) and Focal Muscular Atrophies What to Read Next on Medscape ...
SAFETY AND EFFICACY OF ZIMURA® FOR AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY HAVE NOT BEEN ESTABLISHED. PLEASE ... GATHER2 is the second phase 3 trial of Zimura® in geographic atrophy associated with age-related macular degeneration. ...
OMIQs Clinical Research Unit will participate this year in an international clinical study for geographic atrophy associated ... Geographic atrophy associated with AMD: Omiq participates in clinical study. 28/07/2020. Omiqs Clinical Research Unit (VOR) ... Patients diagnosed with geographic atrophy associated with secondary AMD are eligible for the study. OMIQ ophthalmology ... Inicio / News / Geographic atrophy associated with AMD: Omiq participates in clinical study ...
VIDEO: Real-world geographic atrophy data analyzed. by Healio ophthalmology • 2020/11/14. • 0 Comments ... discusses the results from his study evaluating geographic atrophy in real-world clinical practice using new findings from the ...
What is geographic atrophy?. Geographic atrophy is the advanced form of dry AMD and is characterized by the presence of retinal ... The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and ... results in retinal tissue atrophy called geographic atrophy (GA). In wet AMD, choroidal neovascularization (CNV) develops in ... Geographic atrophy will appear hyper-reflective on NIR imaging.21 NIR is useful in identifying the boundaries of the lesion, ...
Geographic Atrophy (GA). *Glaucoma *Types of Glaucoma. *How Does Glaucoma Damage My Eyes ...
More in Geographic Atrophy (GA): A Closer Look. *. What to know about OCT for macular degeneration ...
FAF-Blue image of geographic atrophy * FAF-Green image of dry age-related macular degeneration ...
... M. Nassisi. Primo. ; ... Purpose To evaluate the correlation between the choriocapillaris (CC) flow alterations around geographic atrophy (GA) and the ... Purpose To evaluate the correlation between the choriocapillaris (CC) flow alterations around geographic atrophy (GA) and the ... Choriocapillaris flow impairment surrounding geographic atrophy correlates with disease progression / M. Nassisi, E. ...
More in Mastering Your Geographic Atrophy (GA) Care. *. Early Signs of Macular Degeneration and How to Treat ...
Geographic Atrophy]. The purpose of this study is to evaluate the long-term safety and tolerability of intr ... Macular Degeneration, Age-Related, Geographic Atrophy Condition Official Title A Multicenter, Open-Label Extension Study to ... A Study Assessing the Long-Term Safety and Tolerability of RG6147 in Participants With Geographic Atrophy Secondary to Age- ... in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who completed the parent study ...
"Geographic atrophy remains an important unmet medical need in ophthalmology. As several new agents are being developed for the ... Geographic Atrophy. *. High-resolution optical coherence tomography improves precision in AMD diagnosis ... Up to 60% of patients with geographic atrophy failed to return for a follow-up visit after 2 years, according to data presented ... Home Follow-up visit adherence may be issue in patients with geographic atrophy ...
Complement Inhibition in Geographic Atrophy: Slowing Progression With Novel Treatments (June 22 CE Webinar). ... Complement Inhibition in Geographic Atrophy: Slowing Progression With Novel Treatments (June 22 CE Webinar). ... Identify the features of geographic atrophy on imaging. *Review clinical trial data for therapy that targets complement for ... Recognize epidemiologic indicators of patients who may be at higher risk for geographic atrophy ...
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023. July 24, 2023. Company to hold investor ... Title: Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration with Intravitreal ANX007: Results of the ... today announced the company will present results from the ongoing ARCHER Phase 2 trial in patients with geographic atrophy (GA ...
What is Geographic Atrophy?. Geographic atrophy is a later stage of dry macular degeneration. It leads to permanent vision loss ... The regions appear like atrophy and resemble a map, hence geographic atrophy. The regions of atrophy lead to a blind spot. It ... Patients with geographic atrophy lose their RPE cells. Replacing the cells will help to restore the photoreceptor outer segment ... Your doctor can ask you to take lutein, zeaxanthin, and zinc to slow the geographic atrophy progress. Taking vitamins such as ...
CTx001 is being evaluated as a potential AAV gene therapy for the treatment of visual impairment due to geographic atrophy ... MHRA awards Complement Therapeutics Innovation Passport for CTx001 to accelerate Gene Therapy for Geographic Atrophy. Written ... an AAV-based gene therapy for the treatment of Geographic Atrophy (GA), has been awarded an Innovation Passport by the UKs ... is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of ...

No FAQ available that match "geographic atrophy"

No images available that match "geographic atrophy"